Bavarian Nordic reports positive data from Phase II Covid-19 booster trial
Denmark
Zealand Pharma reports data from Phase III short bowel syndrome trial
In the trial, 65.7% of subjects in the twice-weekly glepaglutide arm had a clinically meaningful response.
Bavarian Nordic starts Phase II Covid-19 booster vaccine study
Bavarian Nordic’s Covid-19 vaccine yields positive Phase I/II data
Novo Nordisk reports positive data from type 2 diabetes medicine trial
Novo Nordisk to restart Phase III haemophilia trials of concizumab
Orphazyme finds reduced Niemann-Pick disease progression in trial
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
